Global Metabolic Partnering 2014 to 2020 provides the full collection of Metabolic disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
Trends in Metabolic partnering deals Financial deal terms for headline, upfront and royalty by stage of development Metabolic partnering agreement structure Metabolic partnering contract documents Top Metabolic deals by value Most active Metabolic dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.
The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Metabolic dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Metabolic dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Metabolic deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Metabolic dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Metabolic deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2014. The chapter is organized by specific Metabolic therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Metabolic partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Metabolic technologies and products.
Report scope Global Metabolic Partnering 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Metabolic trends and structure of deals entered into by leading companies worldwide.
Global Metabolic Partnering 2014 to 2020 includes: Trends in Metabolic dealmaking in the biopharma industry since 2014 Analysis of Metabolic deal structure Access to headline, upfront, milestone and royalty data Access to hundreds of Metabolic deal contract documents Comprehensive access to over 1000 Metabolic deal records The leading Metabolic deals by value since 2014 Most active Metabolic dealmakers since 2014
The report includes deals for the following indications: Acromegaly, Addison’s disease, Cirrhosis, Cushing’s syndrome, Diabetes, Type 1, Type 2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders, Gynaecomastia, Inborn errors of metabolism, Phenylketonuria, Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia, Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease, Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders, Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic indications.
In Global Metabolic Partnering 2014 to 2020, available deals and contracts are listed by: Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Metabolic Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 1000 metabolic deals. Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are the sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Pancreatic Cancer Diagnostic Tests pipeline products...
Rotavirus Infections - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Pipeline Review, H2 2020, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape. Rotavirus is a virus that infects...
Cardiac Marker Tests - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Cardiac Marker Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Cardiac Marker Tests pipeline products with comparative analysis of the products...
Aryl Hydrocarbon Receptor - Pipeline Review, H2 2020 Summary Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 27 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes....
The Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies. Trends...
The Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors...
The Global Genomics Partnering Terms and Agreements 2014 to 2020 report provides an understanding and access to the Genomics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Genomics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage...
The Global Proteomics Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Proteomics partnering deals Disclosed headlines, upfronts, milestones and royalties by...
